文献速递妇科

醋酸乌利司他与醋酸亮丙瑞林治疗日本症状性子宫肌瘤的III期随机对照试验

Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
PubMed 文献 · Fertil Steril · 2021-03-11

主要终点为闭经35天的患者百分比,UPA组为87.0%,LEU组为81.8%,证实UPA非劣效于LEU;不良事件发生率UPA组78.0%,LEU组88.8%。结论认为UPA对亚洲患者具有临床实用性。

要点

  • UPA 10mg每日口服12周致闭经35天率达87.0%,非劣效于LEU。
  • UPA组不良事件发生率78.0%,与LEU组88.8%相当。
  • UPA对日本症状性子宫肌瘤患者月经过多疗效与LEU可比。

核心结论

  • UPA对日本症状性子宫肌瘤患者的月经过多疗效与LEU相当,且未出现值得关注的不良事件。

主要发现

  • 闭经35天的患者百分比UPA组为87.0%,LEU组为81.8%,UPA非劣效于LEU。
  • 不良事件发生率UPA组为78.0%,LEU组为88.8%。

关键数值与推荐

  • UPA组口服UPA 10mg每日一次,共12周;LEU组皮下注射LEU 1.88mg或3.75mg,在第0、4、8周给药。
  • 主要终点为闭经35天的患者百分比。

临床怎么用

  • 对于日本症状性子宫肌瘤患者,UPA 10mg每日口服12周可作为LEU的替代选择,疗效非劣效且不良事件发生率相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of ulipristal acetate (UPA) for uterine fibroids (UFs), a phase III study was conducted with leuprorelin (LEU) as a comparator. This is the first confirmatory trial of UPA for UFs among Asians. DESIGN: Multicenter, randomized, double-blind, double-dummy, parallel-group study. SETTING: Thirty-two sites in Japan. PATIENT(S): Patients were assigned to 2 arms, with 82 patients in the UPA group and 79 patients in the LEU group. INTERVENTION(S): In the UPA group, 10 mg of UPA was orally administered once a day for 12 weeks. In the LEU group, 1.88 mg or 3.75 mg of LEU was subcutaneously administered at weeks 0, 4, and 8. MAIN OUTCOME MEASURE(S): The primary endpoint was the percentage of patients with amenorrhea for 35 days. For safety evaluation, adverse events (AEs) were recorded. RESULT(S): The percentage of patients with amenorrhea for 35 days was 87.0% in the UPA group and 81.8% in the LEU group, and the efficacy of UPA for causing amenorrhea for 35 days was confirmed to be noninferior to that of LEU. AEs occurred in 78.0% of the patients in the UPA group and 88.8% of the patients in the LEU group. CONCLUSION(S): The effect of UPA on heavy menstrual bleeding was shown to be comparable with that of LEU in Japanese patients with symptomatic UFs. No notable AEs occurred because of the UPA treatment, and the incidence of AEs in the UPA group was comparable with that of AEs in the LEU group. This result demonstrates the clinical utility of UPA for Asians.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Osuga Y, Nakano Y, Yamauchi Y, et al. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial. Fertil Steril. 2021. PMID: 33715871. doi:10.1016/j.fertnstert.2021.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。